Congratulations to Generation Bio Sr. Scientist Anthony Dawson for his presentation at the Cell & Gene Therapy International / BioProcess International Conference last week! Anthony discussed our Rapid Enzymatic Synthesis (RES) process, which is designed to significantly improve the speed, quality, and scalability of DNA manufacturing compared to traditional cell-based methods. If you missed it, you can check out the slides from Anthony's presentation on our website: https://lnkd.in/eDnPmsRK #BioProcessInternational?#BPI2024 #CGT2024
Generation Bio
生物技术研究
Cambridge，Massachusetts 12,523 位关注者
We’re pushing the limits of genetic medicine. And our goal is no limits.
关于我们
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel immune-quiet DNA called iqDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce iqDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
- 网站
-
https://www.generationbio.com
Generation Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2016
- 领域
- Biotechnology、Rare Disease、Gene Therapy、LNPs、DNA和Non-Viral Gene Therapy
地点
-
主要
获取路线
301 Binney Street
4th Floor
US，Massachusetts，Cambridge，02142
Generation Bio员工
动态
-
We are pleased to announce the latest progress in our mission to unlock the full potential of genetic medicine through the latest advancements with our cell-targeted LNP (ctLNP) platform. Learn more in our press release here: https://lnkd.in/eiwzBrAz
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform - Generation Bio
investors.generationbio.com
-
Today, Generation Bio announced an exciting step forward in our mission to realize the full potential of non-viral DNA therapeutics with the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). Read our press release here to learn more: https://lnkd.in/eN8axuDw
-
-
Last week, our Chief Scientific Officer, Matthew Stanton, discussed the key hurdles for non-viral DNA delivery and innate immune stimulation, as well as strategies to address these challenges in an online webinar with the Oligonucleotide Therapeutics Society. Check it out here to learn more:?https://bit.ly/45yQjxs
-